Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Sorafenib in RAI-Refractory Thyroid Cancer
NCT01025453Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2009
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temsirolimus in thyroid cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2009; status: completed.
02
Drugs
temsirolimus
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT01025453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01025453.